3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
28
Colorectal Neoplasms
8
Lung Neoplasms
7
Neoplasms
6
Melanoma
5
Thyroid Neoplasms
3
Pancreatic Neoplasms
3
Glioma
3
Adenocarcinoma of Lung
3
Rectal Neoplasms
2
Ovarian Neoplasms
2
Multiple Myeloma
2
Hematologic Neoplasms
2
Colonic Neoplasms
2
Breast Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sexual Dysfunction, Physiological
1
Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer
1
Prostatic Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasm Metastasis
1
Interventions
Pemetrexed
6
Cisplatin
4
Carboplatin
4
pembrolizumab
3
pralsetinib
2
osimertinib
2
entinostat
2
atezolizumab
2
Paclitaxel
2
130-nm albumin-bound paclitaxel
2
trametinib
1
siltuximab
1
repotrectinib
1
ficlatuzumab
1
enzalutamide
1
durvalumab
1
dabrafenib
1
cobimetinib
1
cemiplimab
1
Vemurafenib
1
Taxes
1
Nivolumab
1
Injections
1
Gemcitabine
1
Gefitinib
1
Docetaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Histologic Type
×
trametinib
×
Thoracic
×
Clear all
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled